坦桑尼亚国家行动计划前系统性抗菌药物消费的基准测试,1998-2005:历史纵向定义的每日剂量分析
Raphael Z Sangeda1, Auleria W Kadinde1, Akida Khea2,3
1Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, TZA.
Cureus
|January 9, 2026
概括
本研究确定了坦桑尼亚1998-2005年抗菌药物消费 (AMC) 的第一个国家基线. 调查结果显示,主要使用的是抗菌药物,为未来的抗菌药物管理计划提供了关键数据.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 在2017年抗微生物耐药性国家行动计划 (NAP-AMR) 之前,坦桑尼亚的有限的历史抗微生物消费 (AMC) 数据.
- 数据的稀缺性阻碍了对过去的抗微生物药物使用模式的理解.
研究的目的:
- 建立坦桑尼亚系统性AMC的国家基线.
- 使用世界卫生组织定义的每日剂量 (DDD) 方法来评估AMC.
- 提供1998年至2005年的数据.
主要方法:
- 对抗微生物药物进口记录的回顾性纵向分析.
- 数据来源于坦桑尼亚药品和医疗器械管理局.
- 消费量表示为每1000名居民每天的DDD (DID).
主要成果:
- 在1998年至2005年期间,每年的AMC从0.45到13.32DID不等.
- 抗菌药物构成了大多数AMC (82.6%).
- 口服配方和Access类抗生素占主导地位.
结论:
- 历史的AMC估计为坦桑尼亚提供了有价值的基准.
- 为未来的抗微生物药物管理计划提供信息.
- 为评估NAP-AMR的影响提供了背景.
关键词:
抗生素 抗生素是一种抗生素.抗微生物耐药性 抗微生物耐药性抗微生物药物管理管理定义的每日剂量.系统性抗微生物药物在TfdaTfda这就是Tmda tmda.使用利用利用利用利用利用利用利用利用利用更多相关视频
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
Pulmonary Tuberculosis V
532
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
532
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
231
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
231
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
227
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
227
Antimicrobial Effectiveness
897
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
897
Dosage Regimens: Partial Pharmacokinetic Parameters
147
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
147


